

GEROSTATE ALPHA (YC S18)

## A pharmaceutical company dedicated to treating aging and age-related disease

☒ PITCH VIDEO ☐ INVESTOR PANEL



[gerostatealpha.com](http://gerostatealpha.com) San Francisco CA

Technology

Moonshots

Healthcare

Y Combinator

Bio Tech

... ..

### Highlights

- 1 💰 \$2.1M raised in initial seed round, at \$15M valuation cap
- 2 🧬 Team at the forefront of aging research for decades, collectively authoring 200+ papers
- 3 📈 Our platform delivers drug candidates to slow aging at a success rate of 20%
- 4 🧪 Funds will be used to test our candidates in aging mice

## Our Team



**Simon Melov** CEO

PhD; Professor at Buck Institute for Research on Aging & CEO of Gerostate Alpha

We know how to stop the threat of chronic disease; and we care because aging is 100% fatal



**Mark S Lucanic** CTO

PhD; Expert in small molecule and genetic screens including significant experience with high throughput technologies, and has utilized simple model organisms to explore pharmacological extension of lifespan.



**Gordon Lithgow** Professor, Vice President Buck Institute

PhD; Chief Academic Officer at the Buck Institute for Research on Aging and specializes in the properties of small molecules to extend lifespan, having been internationally recognized for his work on aging with numerous awards and prizes.

## Pitch



**Gerostate** *Alpha*  
We make drugs for Aging

# The Best Place in the World for an Aging Company

- Incubating at the Buck Institute for Research on Aging in Novato, CA
- Unique facilities and equipment for aging research
- World class expertise and research environment



Sunrise over the Buck Institute for Research on Aging



## Co-founders of Gerostate Alpha



**Simon Melov PhD**  
CEO



**Mark Lucanic PhD**  
CTO



**Gordon Lithgow PhD**  
Professor, Vice President  
Buck Institute

Forefront of aging research for decades  
200+ papers



[www.gerostatealpha.com](http://www.gerostatealpha.com)


Raised more than \$100m in NIH  
and corporate sponsored research

## Edward Lanphier, former CEO Sangamo Therapeutics Gerostate Alpha Executive Chair

Solo founder of Sangamo Therapeutics  
Investor in Gerostate Alpha  
Led Sangamo for over 20 years  
Pioneered genome engineering as a therapeutic modality  
Multiple clinical trials  
Multiple pharma partnerships at Sangamo  
Led Sangamo to multi billion dollar valuation



[www.gerostatealpha.com](http://www.gerostatealpha.com)



Function  
declines with  
age from your  
20's




Gerostate Alpha

## We want to *Slow* tissue aging




3 synergistic approaches: Novel interventions, FDA/EMA off-patent drugs, natural products



Gerostate Alpha


State of the art deep phenotyping to determine efficacy of interventions

- Cardiovascular
- Bone
- Metabolic
- Neurological
- Pulmonary
- Muscular



Gerostate Alpha

Unbiased drug development pipeline, addressing multiple functional domains of aging



## Our platform delivers drug candidates to slow aging

- We screened 61,000 compounds for lifespan extension in our platform
- We have 30 hits which extend lifespan in our simple animal model
- We trialed 5 of these hits in aged mice for slowed aging
  - 6 month treatment from 20 months-26 months of age
  - 1 out of 5 resulted in measurable slowing of a major aging tissue (bone)


## OUR PLATFORM DELIVERS HITS AT 20% SUCCESS RATE!

## Milestones

- Currently testing high value candidates for cell toxicity
- Trial 10-15 compounds in mice for lifespan extension and slowed aging over the next 12 months
- Lead optimization covering diverse/novel targets of aging; identify novel targets and pathways (12 months)
- Evaluate efficacy in preclinical diseases/syndromes (12-24 months), complete preclinical toxicology testing & pharmacokinetics
- IND enabling Phase 1 (24/36 months)



## Business development strategy



## Fundraising

\$2.1M raised in initial seed round, at \$15M valuation

\$460,000 raised in last round (August 21)

New round starting late Sept, at \$20M valuation cap

We are super Capital efficient!

New funds will be used to test 10-15 of our hits in aging mice